Your Favorite Baby Shampoo does it again

The world’s largest healthcare maker, Johnson & Johnson (JNJ), released its quarterly earnings this morning. Fourth quarter revenue came in at $17.81 billion, below analyst revenue estimates but beating net income expectations. Excluding non-recurring events, worldwide sales increased 7.8% and domestic sales at 13.4%. Most of the growth in 2015 had come from the company’s pharmaceutical and consumer products divisions. The downside with being a multi-national corporation is the exposure to foreign currencies, in this case a 6.8% negative impact on earnings.

Last week, Johnson & Johnson announced restructuring plans for its medical devices business, including cutting about 3,000 jobs in the business segment over the next two years. We can expect the cost cutting to continue with pharmaceutical companies as top line revenue will likely remain flat.

About Johnson & Johnson

The company was founded in 1885 in New Brunswick, NJ and operates in three categories: Personal Consumer Care Products, Pharmaceuticals, and Medical Devices. Popular consumer products you may be familiar with are Listerine, Acuvue, Tylenol, and Neutrogena. In pharmaceuticals, J&J specializes in immunology, oncology, neuroscience, cardiovascular and infectious diseases. The medical devices segments focuses on diagnostics, orthopedics such as hips and knees, and general/advanced surgeries.